Refractory patients previously treated with PIs, IMiDs, or both showed ORRs above 65%.
Ixazomib, either alone or in combination with dexamethasone, produced a PR or better in approximately one third of patients with relapsed MM and limited previous exposure to bortezomib in this phase II trial.
Continuous lenalidomide plus low-dose dexamethasone significantly extended PFS and OS in transplantation-ineligible patients with newly diagnosed MM.
Adding afuresertib to bortezomib and dexamethasone may overcome bortezomib resistance.
Anti-CD38 antibody at ≥ 10 mg/kg achieved an ORR of 30.9% in patients with CD38+ hematologic malignancies.
Long-term outcome of patients presenting with renal failure significantly improved with bortezomib-based induction and maintenance therapy vs vincristine/thalidomide regimen with fewer discontinuations of maintenance therapy due to toxicity.
This final analysis confirms previously demonstrated significant PFS and OS benefits with POM plus LoDEX vs high-dose dexamethasone in a patient population with relapsed/refractory MM. High‐risk cytogenetics did not impact median PFS for patients receiving POM plus LoDEX. In this heavily pretreated population, 9% of POM plus LoDEX patients had a duration of therapy (DoT) > 12 months.
In this phase I/II study, twice-weekly dosing of ixazomib in combination with lenalidomide/dexamethasone was feasible and active
Despite similar response rates and survival, MPR had a worse safety profile compared with CPR and Rd, including higher rates of hematologic adverse events, in this phase III trial.
When used in both induction and consolidation, combination carfilzomib/thalidomide/dexamethasone produced responses in 96% of patients, including very good PR or better in 84%.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.